Zhongguancun 'Spark' activity walks into Peking University Cancer Hospital

Updated: Mar 17, 2023 L M S

As a part of the "Spark" series of events in Zhongguancun, the third Technology Achievement Promotion Conference was recently held at the Peking University Cancer Hospital. It was jointly hosted by the Beijing Science and Technology Achievement Transformation Service Center, the Zhongguancun Technology Manager Association, and other institutions.

Li Ziyu, director of the Peking University Cancer Hospital, introduced the pilot work of small and medium-sized enterprises in taking over the technology achievements of medical and health institutions with a "use first, pay later" policy, as well as the practical experience contributed by the hospital by participating in the "Spark" series of activities in Zhongguancun and promoting the transformation of scientific and technological projects.


Participants listen attentively at the third Technology Achievement Promotion Conference [Photo/bjzpark.spotlightbeijing.com]

Huang Jing, national executive director of AstraZeneca China's Key Customers and Hospital Access Team, mentioned the company's experience and practices in promoting technological innovation and achievement transformation: first, it has conducted full-process management with hospitals to promote integrated diagnosis and treatment of severe diseases; second, it has established a 1 billion yuan ($144.96 million) medical technology and innovation fund with China International Capital Corporation.

Zheng Lin from the Beijing Municipal Science and Technology Commission and the Zhongguancun Administrative Committee's Achievement Transformation Department presented the policy innovation supporting Beijing's science and technology achievement transformation work. 

In the achievement promotion section, six technical achievements in various fields from Peking University Cancer Hospital participated in the roadshow.

For instance, Yang Zhi, director of the Nuclear Medicine Department, showcased the development and industrialization of the "SSTR2-targeted diagnosis and treatment integrated probe" project, and Jie Yuntao, director of the Familial Genetic Tumor Center, displayed the project "A new method for discovering large fragment rearrangements of BRCA1/2 using second-generation sequencing". 

During the open communication session, guests from financial institutions, universities, scientific and technological enterprises, and professional service organizations actively spoke and had heated discussions with project teams on their respective concerns.